The Latest News
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.>
- NAYZILAM® (midazolam) nasal spray* is a nasally administered benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.
- NAYZILAM allows for administration by a non-healthcare professional in patients actively seizing when and where a seizure cluster occurs.
- Approval of NAYZILAM adds to UCB’s already existing anti-epilepsy drug portfolio, reinforcing the company’s position as a global leader in epilepsy.
Lupus Patients with Elevated PC4d Levels Have Significantly Increased Occurrence of Thrombosis
Alphatec Announces Sales Leadership Appointment And Successful Closing Of Expanded Credit Facility With Squadron Capital>
Experienced Spine Executive David Sponsel Assumes Sales Leadership Role
IdentiTi implants are 60% porous, which enhances intra-operative and post-operative imaging.
Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018
ElectroCore Announces Encouraging Research Supporting Key Areas of Clinical Development for its Non-Invasive Vagus Nerve Stimulator, gammaCore™>
Data presented at the 3rd International Brain Stimulation Conference support the use of nVNS for treatment of mild traumatic brain injury and rheumatoid arthritis
Dr. Tony Fiorino to serve as Chief Medical Officer and Brian Posner as Chief Financial Officer
Exagen and the Lupus Foundation of America Partner on New Initiative to Reduce the Time to an Accurate Lupus Diagnosis>
New tools and resources will be shared in English and Spanish through physican offices, websites and social media.
gammaCore may be medically necessary for the abortive treatment of episodic migraine and episodic cluster headaches
Addresses Significant Unmet Needs In Spine Surgery
Patient Program to Increase Awareness of Non-Drug Migraine Therapies
Findings Support the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults
Increasing Support of the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults
Collaboration to drive greater awareness about challenges facing lupus diagnosis and management
Five-year contract makes gammaCore™ available to the over 21 million patients managed within the Department of Veteran’s Affairs,
ElectroCore Receives FDA Clearance for gammaCore™ (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults>
First and only product
New design and development facility to support increasing patient demand.
Fnancial results for the three months and nine months ended
Results for the third quarter ended